How Remission Is Confirmed After Lymphoma Treatment and Then Monitored Over Time

The last infusion bag empties, a nurse unhooks the line, and someone on the ward says “that’s it, you’re done.” Except it rarely feels done. Most people walk out of that room carrying one question they did not have on day one: how will anyone actually know the lymphoma is gone?

It is a fair question, and the honest answer is more interesting than a single scan and a handshake. Confirming remission is a careful process with its own timing rules, its own scoring system and its own known blind spots. Lymphoma remission follow up is then a years-long relationship with a clinic, one that changes shape as the risk of relapse changes.

This explainer walks through what happens, in what order, and why. It also tackles the questions people type into search engines late at night, from late relapses to second cancers to whether life ever feels ordinary again.

What does lymphoma remission actually mean?

Remission is a clinical judgment, not a promise. It means that after treatment, tests can no longer find active lymphoma, or find much less of it than before. Doctors split this into two main categories, and the difference matters for everything that follows.

Complete remission (often written CR) means no evidence of disease on scans, examination and blood tests, with any remaining lymph node enlargement judged to be inactive scar tissue rather than living tumour. Partial remission (PR) means the lymphoma has shrunk substantially but measurable disease remains. Stable disease and progressive disease describe the less welcome outcomes.

Since the introduction of the Lugano classification, an international consensus for staging and response assessment, most centres also describe remission in terms of metabolism, meaning how much sugar-based tracer the tissue takes up on a PET scan. A “complete metabolic response” means the tissue is no longer behaving like active lymphoma even if a shadow persists on the pictures.

Two further phrases come up in clinic. “Remission” is not the same as “no cancer cells anywhere”; current tests cannot see individual cells, so a very small hidden population may remain. That is why follow-up exists. And “durable remission” simply means the remission has lasted a long time; the longer it holds, the lower the yearly risk of relapse for most fast-growing lymphoma types, according to the NHS and Mayo Clinic overviews.

What matters most, in my view, is that patients ask their team which category applies to them and what evidence supports it. “You’re in remission” and “you had a complete metabolic response with a Deauville score of 2” are the same news delivered at very different levels of detail, and the second version equips you to understand every conversation afterwards.

How is remission confirmed after lymphoma treatment? What actually happens

Confirmation is a bundle of checks, not one event. It typically starts a few weeks after the final cycle of treatment, once the body has had time to settle and inflammation from therapy has faded.

The centrepiece for most Hodgkin lymphoma and many aggressive non-Hodgkin lymphomas is a PET-CT scan. A radioactive sugar tracer is injected, highly active cells absorb more of it, and the PET camera maps that uptake onto a CT picture of the anatomy. Lymphoma cells are usually greedy for glucose, so residual disease tends to light up. For lymphoma types that are not reliably PET-avid, such as some slow-growing subtypes, a CT scan with contrast is used instead, as Mayo Clinic and the Lugano recommendations describe.

Alongside imaging, the team repeats the physical examination, feeling for nodes in the neck, armpits and groin and checking the spleen and liver. Blood tests look at counts of red cells, white cells and platelets, plus markers such as lactate dehydrogenase (LDH), an enzyme released by rapidly turning-over cells.

If the bone marrow was involved at diagnosis, a repeat marrow sample may be requested to confirm it has cleared, although the Lugano guidance allows PET-CT to replace marrow biopsy in many Hodgkin and diffuse large B-cell cases. And if a scan shows a suspicious spot that could be either residual lymphoma or inflammation, the safest route is often a biopsy of that spot rather than a guess. Guidelines specifically caution against changing treatment on the basis of a scan alone when a biopsy is feasible.

The results are then discussed at a multidisciplinary meeting, where haematologists, radiologists and pathologists agree a response category. Only then does the word “remission” get written in the notes.

PET scan after lymphoma treatment: why timing and scoring matter

A PET scan performed too early can lie. Chemotherapy and radiotherapy provoke inflammation, and inflamed tissue also gulps sugar tracer, so an early scan may show glowing areas that are simply healing. The Lugano recommendations therefore advise waiting at least 3 weeks, and preferably 6–8 weeks, after chemotherapy, and 8–12 weeks after radiotherapy, before the end-of-treatment PET-CT (Cheson and colleagues, PubMed).

Radiologists read the result using the Deauville five-point scale, which compares the brightest residual spot with two internal reference points in the same body: the blood pool in the large vessels of the chest and the liver.

• Score 1: no uptake above background.
• Score 2: uptake at or below the mediastinal blood pool.
• Score 3: uptake above the blood pool but at or below the liver.
• Score 4: uptake moderately higher than the liver.
• Score 5: uptake markedly higher than the liver, or new lesions.

Under Lugano, scores of 1 to 3 at the end of treatment are generally considered a complete metabolic response, while 4 and 5 suggest residual disease and prompt further discussion, often a biopsy. The scale exists to make different hospitals and different radiologists speak the same language, so a result travels well between teams.

Two practical notes help patients. First, a lump that is still visible on CT but scores 1 to 3 on PET is usually scar tissue; the Cleveland Clinic explanation of PET scans describes this distinction between size and activity. Second, brown fat, infection, recent exercise and some medicines can all create false bright spots. Radiologists know this and factor it in, which is one reason a single ambiguous scan rarely settles the question on its own.

Who is usually offered end-of-treatment testing, and who is asked to wait?

Almost everyone who completes a course of treatment intended to eliminate detectable lymphoma will be offered a formal response assessment. The variation is in the type and timing of the tests.

Patients with Hodgkin lymphoma or an aggressive non-Hodgkin lymphoma, such as diffuse large B-cell lymphoma, are usually scheduled for PET-CT in the window described above, because these subtypes are reliably PET-avid and a complete metabolic response carries real prognostic weight. Many also have an interim PET partway through chemotherapy, used by the team to judge how the disease is responding.

People with slow-growing (indolent) lymphomas, such as follicular lymphoma or small lymphocytic lymphoma, often receive CT-based assessment instead, and the aim of treatment for them is commonly long-term control rather than complete eradication, as the NHS describes for non-Hodgkin lymphoma. Their “remission” may be defined by shrinkage and absence of symptoms.

Who is asked to wait? Three groups come up repeatedly.

• Those who finished treatment very recently, because a premature scan risks a false positive, so the team deliberately delays imaging.
• Those recovering from an infection or with very low blood counts, since infection can mimic lymphoma on PET and the body needs to stabilise.
• Those on active surveillance (“watch and wait”) for an indolent lymphoma who have not had treatment at all; for them there is no end-of-treatment scan, only scheduled monitoring.

Waiting can feel unbearable when you want an answer. But a scan booked in the right window is far more likely to give a clear result, and a clear result is the one thing that reduces the chance of an unnecessary biopsy or an anxious “repeat in three months”. The treating team decides the timing, and it is entirely reasonable to ask them to explain why they chose it.

Lymphoma remission follow up: what the schedule usually looks like

Once remission is confirmed, the pattern of care changes. Visits are frequent early, when the risk of relapse is highest for fast-growing lymphomas, and then stretch out. Exact intervals vary by subtype, stage at diagnosis, treatment received and local protocol, so the table below shows a typical shape rather than a rule. The NHS and Mayo Clinic both describe regular follow-up appointments that become less frequent over time; the Lugano recommendations set out the principle that routine scans should be limited in patients without symptoms.

Period after remission	Typical visit pattern	What usually happens
First 2 years	Roughly every 3 months	History, examination, blood counts and LDH; scans only if a concern arises
Years 3 to 5	Roughly every 6 months	Same core checks; attention shifts toward late effects
Beyond 5 years	Annually, or discharge to primary care with a written plan	Late-effects screening: thyroid, heart, second-cancer checks as indicated

Notice what the middle column does not say: no scheduled scan every visit. For most people in complete remission, the follow-up visit is a conversation and a blood test. The team asks about new lumps, fevers, drenching night sweats, unexplained weight loss, persistent itch or unusual fatigue, then examines the node areas and spleen.

Indolent lymphomas follow a different logic. Because they can relapse many years later and often behave gently, follow-up may continue indefinitely at a low frequency, sometimes with periodic imaging if a particular site is being watched.

Ask for your own plan in writing, including who to contact between visits. A schedule you understand is a schedule you can keep.

Why are routine surveillance scans used sparingly after remission?

Many patients assume more scans mean more safety. The evidence points the other way for most people in complete remission, and the reasoning deserves a fair hearing.

First, most relapses of aggressive lymphoma are found because the patient notices something, not because a scheduled scan catches it silently. The Lugano consensus notes that the majority of relapses are detected by symptoms, examination or blood tests between planned imaging, and it advises against routine surveillance scans in asymptomatic patients with Hodgkin lymphoma and diffuse large B-cell lymphoma after a complete response (Cheson and colleagues, PubMed).

Second, scans carry costs of their own that have nothing to do with money. Each CT delivers ionising radiation, and repeated exposure adds up over years in people who may already have received radiotherapy. Scans also produce incidental findings, small nodules or bright spots that turn out to be nothing but generate biopsies, anxiety and delay.

Third, there is no convincing evidence that detecting a relapse a few weeks earlier on a scan improves how well salvage treatment works in these subtypes. Relapsed aggressive lymphoma tends to announce itself.

This does not mean scans disappear from follow-up. They are used when something changes: a new lump, persistent unexplained symptoms, a rising LDH, or a specific residual area the team agreed to watch. Some indolent subtypes and some clinical trial protocols also include planned imaging. The point is that imaging is targeted, not reflexive.

If your team is not scanning you regularly, that is usually a sign that they consider your remission solid and are following guideline practice, not a sign of neglect. It is still worth asking them to explain their approach so the absence of a scan does not feel like an absence of care.

How does follow-up differ between Hodgkin and non-Hodgkin lymphoma?

Lymphoma is dozens of diseases sharing a name. The NHS and MedlinePlus both describe the broad split: Hodgkin lymphoma, identified by a particular abnormal cell under the microscope, and non-Hodgkin lymphoma, an umbrella for many subtypes ranging from very slow to very fast growing. Follow-up reflects those differences.

Hodgkin lymphoma often affects younger adults and is usually treated with a defined course of chemotherapy, sometimes followed by radiotherapy. When a complete metabolic response is achieved, most relapses occur within the first two to three years, so early follow-up is intensive and later follow-up pivots to long-term health. Because many patients are young at treatment and may live for decades afterwards, late effects on the heart, lungs, thyroid and fertility receive particular attention in Hodgkin follow-up clinics.

Aggressive non-Hodgkin lymphoma, such as diffuse large B-cell lymphoma, follows a broadly similar early pattern: PET-based confirmation, close review for the first two years, then spacing out. Age at diagnosis is often higher, so follow-up also overlaps with management of other conditions such as heart disease or diabetes.

Indolent non-Hodgkin lymphoma, including follicular and marginal zone lymphomas, behaves differently. Remissions can be long but relapse remains possible many years later, and some people cycle through periods of treatment and observation over decades. Follow-up here is usually lifelong, often with blood tests and examination, and some people never need a second course of treatment.

Treatments also shape follow-up. Anyone who received a stem cell transplant, a T-cell-based immunotherapy, or high-dose chest radiotherapy has an extra layer of monitoring for infection risk, organ function and revaccination needs, which the treating team will set out individually. Knowing your exact subtype, stage and treatment is the key to understanding why your plan looks the way it does.

Can lymphoma come back after 10 years? Understanding relapse patterns

Yes, it can, though how likely that is depends heavily on the subtype. This is one of the most searched questions about lymphoma remission, and it deserves a nuanced answer rather than a reassuring dismissal.

For Hodgkin lymphoma and aggressive non-Hodgkin lymphomas that achieved complete remission, the risk of relapse is concentrated in the first two to three years and falls steadily afterwards. Late relapse beyond five years is uncommon, and beyond ten years it is rare, which is why guideline follow-up thins out and often transfers to primary care. Uncommon does not mean impossible, and the NHS advises anyone previously treated for lymphoma to report new symptoms promptly at any point.

Indolent lymphomas are a different story. Follicular lymphoma, for example, is well known for recurrences that can appear a decade or more after the first treatment. Many people live with it as a long-term, relapsing and remitting condition rather than something that ends. This is why some follow-up clinics keep indolent-lymphoma patients on their books indefinitely.

A second nuance: what looks like a late relapse is sometimes a new, different lymphoma, or a transformation, in which an indolent lymphoma changes into a faster-growing type. Only a biopsy can tell the difference, and the distinction changes treatment, so teams will almost always want tissue before acting.

What should a person ten years out actually do? In practice, live normally but keep three habits: know the warning signs listed in the “When to call your doctor” section, keep any long-term late-effects screening the team recommended, and make sure any new doctor you see knows your lymphoma history. That history should follow you into every medical record for the rest of your life.

What do the first weeks and months after remission usually look like?

Being told you are in remission is not a finish line so much as a change of gear. The body has been through months of treatment, and recovery has its own timeline that has little to do with the scan result.

The first few weeks. Blood counts are often still recovering, so infection risk remains higher than normal and tiredness can be profound. Taste changes, numbness or tingling in the fingers and toes (peripheral neuropathy, meaning nerve irritation from certain chemotherapy drugs), and a fuzzy concentration people call “chemo brain” are all common. The Mayo Clinic and NHS both describe these as expected after-effects that usually ease gradually.

Months one to three. Energy typically returns in steps rather than a straight line. Hair regrowth begins. Many people go back to work or study part-time in this window, though this varies enormously with the intensity of treatment and the nature of the job. The first follow-up visit usually happens here, and for many it is emotionally harder than expected: the safety net of weekly hospital contact has gone, and the mind has more space for worry.

Months three to twelve. Physical stamina usually approaches a new baseline. Neuropathy can be slow to settle and sometimes lingers. Sleep, mood and appetite often normalise, but anxiety around scans or check-ups (sometimes called “scanxiety”) is very common and does not mean anything is wrong.

The realistic framing is that the first year after treatment is a recovery year. People who set gentle, graded goals for activity, keep appointments, and ask for help with fatigue or mood early tend to describe the year as manageable rather than lost. Nothing here should be read as a promise; it is simply the shape the months take for many people.

Can lymphoma lead to other cancers? Late effects that follow-up watches for

Lymphoma itself does not turn into a different cancer, but some treatments used against it can raise the long-term risk of other cancers and of organ damage. This is the main reason lymphoma follow-up continues long after the risk of relapse has faded, and both Mayo Clinic and the NHS list late effects as a core part of survivorship care.

Second cancers. Radiotherapy to the chest is associated with an increased later risk of breast cancer, particularly in women treated young, and of lung cancer, especially in people who smoke. Certain chemotherapy classes are linked to a small increase in later blood cancers such as myelodysplasia or acute leukaemia. The absolute risks vary with age, dose and field, so the treating team, not a general article, should quantify them for any individual.

Heart and lungs. Anthracycline chemotherapy can weaken heart muscle over years, and chest radiotherapy can accelerate coronary artery disease and valve problems. Follow-up may therefore include periodic heart checks and blunt advice about blood pressure, cholesterol and smoking.

Thyroid. Radiotherapy to the neck commonly leads to an underactive thyroid years later, which is why a simple annual thyroid blood test is standard in many long-term clinics.

Fertility and hormones. Some regimens affect fertility; this is ideally discussed before treatment, but follow-up clinics revisit it and can refer onward.

Infection and immunity. Treatments that deplete B cells, or a stem cell transplant, can leave antibody levels low for a long time, and revaccination may be advised.

What matters most here is a written late-effects plan. Ask what screening you need, how often, and who orders it once you leave the specialist clinic.

Can you feel normal after lymphoma? Fatigue, immunity and everyday life

Most people eventually describe a life that feels ordinary again, with some caveats worth naming honestly.

Fatigue is the most persistent complaint. Cancer-related fatigue differs from ordinary tiredness; rest does not fully fix it, and it can flare with minor illness or stress. The NHS and Mayo Clinic both describe it as common for months after treatment and note that it tends to improve slowly. Graded physical activity, even short daily walks, is one of the few approaches with consistent evidence of benefit. Persistent fatigue that is getting worse rather than better, however, is worth reporting, since it can occasionally signal anaemia, an underactive thyroid or, rarely, relapse.

Infections. Immune recovery lags behind blood counts. People who received certain antibody treatments may have reduced antibody responses to vaccines for many months. Follow-up teams often advise on timing for influenza and other routine vaccinations and may recommend repeating childhood vaccinations after a transplant. Live vaccines are avoided until the team confirms it is safe.

Mind and mood. Low mood, anxiety and a sense of unreality are common in the first year and are not weakness. Many centres offer psychological support, and it is entirely appropriate to ask.

Work, exercise, alcohol and travel. There is no single rule. In general, gradual return is encouraged, alcohol within standard public health limits is acceptable once liver tests are normal, and travel is fine once counts have recovered; the team will advise on vaccines and on carrying a summary of your history.

Feeling normal, for most people, arrives quietly. One day the follow-up appointment is simply an appointment, not an event. That is a reasonable thing to expect, without anyone promising it.

What people often get wrong about lymphoma remission

Some misunderstandings show up in almost every follow-up clinic. Correcting them makes the whole process less frightening.

“A visible lump on the scan means the lymphoma is still there.” Not necessarily. Treated lymph nodes often leave a residual mass of scar tissue. If PET shows no metabolic activity (Deauville 1 to 3), that mass is usually inert, and Lugano criteria count it as complete metabolic response. Size and activity are different things.

“Fewer scans means my doctors are cutting corners.” Guidelines actively discourage routine surveillance imaging in asymptomatic patients with Hodgkin or diffuse large B-cell lymphoma in complete remission, because most relapses are found clinically and scans bring radiation and false alarms.

“Five years means I can stop thinking about it.” For aggressive subtypes the relapse risk is very low by then, but late-effects screening should continue, and indolent subtypes can recur much later. Follow-up changes focus; it does not simply end.

“Remission and complete remission are the same.” Partial remission means measurable disease remains, and it leads to a different conversation about further treatment or observation. Ask which term applies to you.

“Any swollen node means relapse.” Most swollen nodes after lymphoma are caused by ordinary infections, just as they are in anyone else. A node that persists beyond a few weeks, grows, or comes with other symptoms deserves a call. Panic at every cold does not.

“Diet, supplements or detox programmes can keep lymphoma away.” There is no reliable evidence that any specific food, supplement or alternative regimen prevents lymphoma relapse. A balanced diet, physical activity, not smoking and moderate alcohol support general health and reduce the risk of treatment-related heart disease and second cancers, which is a genuinely worthwhile goal. Anything marketed as a relapse-preventing product should be treated with scepticism and discussed with the team before use.

Questions to ask your care team about follow-up

A good follow-up plan is a shared one. These questions, adapted from the kind of checklist the NHS and Mayo Clinic suggest for after-treatment conversations, help turn a rushed appointment into a plan you actually understand. Take the list with you; write the answers down or ask permission to record them.

• What exactly was my response category, and what tests showed it? If a PET was used, what was the Deauville score?
• Which subtype and stage did I have, and how does that shape my relapse risk over the next few years?
• How often will I be seen, for how long, and what will each visit involve?
• Will I have any planned scans? If not, what would prompt one?
• Which symptoms should make me contact you between visits, and how do I reach the team quickly?
• What late effects am I at risk of given my specific treatment, and what screening do I need for them?
• Do I need any vaccinations repeated or delayed, and when is it safe to have live vaccines?
• Is there anything about fertility, hormones or bone health I should follow up on?
• Who takes over my care if I am discharged to my family doctor, and will they receive a written summary and plan?
• Are there support services for fatigue, mood or returning to work that I can use?
• Is there a clinical trial or registry that might be relevant to my follow-up?

One more, which people rarely ask but should: “If the lymphoma did come back, what would the likely options be?” Knowing that a plan exists, even one you hope never to use, takes much of the sting out of every future check-up. The answer will be individual, and the team is the only right source for it.

When to call your doctor: red-flag signs during lymphoma follow-up

Follow-up works best as a partnership, and your part is to report change rather than to diagnose it. None of the signs below prove relapse; most have ordinary explanations. All of them justify a call to the team or, where indicated, urgent care, rather than waiting for the next scheduled visit. This guidance reflects the warning features described by the NHS, Mayo Clinic and MedlinePlus.

Contact your lymphoma team promptly if you notice:

• A new lump or swelling in the neck, armpit, groin or elsewhere that persists beyond two to three weeks or keeps growing.
• Fevers with no obvious cause, especially recurring over more than a few days.
• Drenching night sweats that soak clothing or bedding.
• Unintended weight loss, particularly if it approaches a tenth of your body weight over a few months.
• Persistent itching without a rash, or fatigue that is steadily worsening rather than improving.
• New breathlessness, a persistent cough, chest discomfort or difficulty swallowing.
• Persistent abdominal fullness, pain under the left ribs, or early satiety, which can reflect an enlarging spleen.
• Unusual bruising, bleeding, or very pale skin, which may indicate low blood counts.

Seek urgent or emergency care immediately if you have:

• A temperature of 38°C (100.4°F) or higher while your team has told you your immunity may be reduced, or shivering and feeling very unwell even without a recorded fever.
• Severe breathlessness, chest pain, or swelling of the face and neck.
• Sudden severe headache, confusion, weakness on one side or new seizures.
• Calf or leg swelling with pain, or sudden chest pain and breathlessness, which can signal a blood clot.

Keep the team’s contact number, and a brief written summary of your diagnosis and treatment, somewhere you can find it quickly. Any decision about further tests or treatment rests with your treating clinicians, and they would far rather hear from you about something that turns out to be nothing than not hear about something that matters.

Frequently asked questions

What does lymphoma remission mean in plain terms?

It means tests can no longer detect active lymphoma, or find much less than before. Complete remission means no evidence of disease on scans, examination and blood tests; partial remission means the disease has shrunk substantially but some remains measurable. Remission does not guarantee every cell is gone, which is why structured follow-up continues afterwards and why the exact category matters.

How long after treatment is the PET scan done to confirm remission?

Usually a few weeks after the last treatment. International Lugano recommendations advise at least 3 weeks, and preferably 6–8 weeks, after chemotherapy, and 8–12 weeks after radiotherapy, so that inflammation from treatment has settled and does not mimic active lymphoma. Your team sets the exact date based on your regimen and recovery.

What is a typical lymphoma follow up schedule after remission?

A common pattern is a visit roughly every three months for the first two years, about every six months to year five, then yearly or transfer to a family doctor with a written plan. Each visit usually includes a symptom review, examination and blood tests rather than a scan. Intervals vary by subtype and treatment, so ask for your own written schedule.

Can lymphoma come back after 10 years?

It can, though it depends on the subtype. For Hodgkin lymphoma and aggressive non-Hodgkin lymphomas in complete remission, relapse this late is rare because most recurrences happen within the first two to three years. Indolent lymphomas such as follicular lymphoma can recur a decade or more later, which is why their follow-up is often lifelong.

Can lymphoma lead to other cancers?

Lymphoma itself does not change into another cancer, but some treatments raise long-term risk of others. Chest radiotherapy is linked to later breast and lung cancer, and certain chemotherapy classes to a small increase in later blood cancers. The size of the risk depends on age, treatment type and dose, so ask your team what screening applies to you.

What are the chances of surviving lymphoma?

There is no single figure, because lymphoma covers dozens of subtypes with very different behaviour, and outlook also depends on stage, age, general health and how the disease responded to treatment. Population statistics describe groups, not individuals, and often lag behind current treatment. Your treating team can explain what the evidence suggests for your specific subtype and response.

Can you feel normal with lymphoma or after it?

Most people gradually return to a life that feels ordinary, usually over the first year after treatment. Fatigue is the slowest symptom to resolve, immune recovery can lag, and anxiety around check-ups is common. Graded activity, keeping appointments and asking early for help with mood or tiredness make the transition easier for many, though the pace is individual.

What lymphoma relapse symptoms should I watch for after remission?

Report a new persistent or growing lump, unexplained fevers, drenching night sweats, unintended weight loss, persistent itch, worsening fatigue, new breathlessness or a persistent cough, or fullness under the left ribs. Most such symptoms have ordinary causes, but any of them justify contacting your team between visits rather than waiting for the next scheduled appointment.

Why am I not having regular scans during follow-up?

Because guidelines discourage routine surveillance imaging in people without symptoms after complete remission of Hodgkin or diffuse large B-cell lymphoma. Most relapses are picked up through symptoms, examination or blood tests, and repeated scans add radiation exposure and false alarms without clear benefit. Scans are reserved for new concerns, which is standard practice rather than a sign of reduced care.

Does a remaining lump on my scan mean the lymphoma is still active?

Not necessarily. Treated nodes often leave scar tissue that stays visible on CT. If the PET component shows no metabolic activity, scored Deauville 1 to 3, the mass is usually inactive and counts as a complete metabolic response under Lugano criteria. If activity is uncertain, teams generally prefer a biopsy of the spot over changing treatment on the scan alone.

References

• Hodgkin lymphoma: Treatment (NHS)
• Lymphoma (MedlinePlus)
• PET Scan (Cleveland Clinic)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.